Abstract:The use of epigenetic bromodomain inhibitors as anticancer therapeutics has transitioned from targeting bromodomain extraterminal domain (BET) proteins into targeting non-BET bromodomains. The two most relevant non-BET bromodomain oncology targets are cyclic AMP response element-binding protein (CBP) and E1A binding protein P300 (EP300). To explore the growing CBP/EP300 interest, we developed a highly efficient two-step synthetic route for dimethylisoxazole-attached imidazo[1,2-a]pyridine scaffold-containing inhibitors. Our efficient two-step reactions enabled high-throughput synthesis of compounds designed by molecular modeling, which together with structure–activity relationship (SAR) studies facilitated an overarching understanding of selective targeting of CBP/EP300 over non-BET bromodomains. This led to the identification of a new potent and selective CBP/EP300 bromodomain inhibitor, UMB298 (compound 23, CBP IC50 72 nM and bromodomain 4, BRD4 IC50 5193 nM). The SAR we established is in good agreement with literature-reported CBP inhibitors, such as CBP30, and demonstrates the advantage of utilizing our two-step approach for inhibitor development of other bromodomains.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c02232?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c02232</a>.Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_001.csv">CSV</a>)BromoSCAN, differential scanning fluorometry (DSF), and cellular activity data of compounds 7, 16, and 23; crystallographic data collection and refinement statistics of compound 23; 1H NMR and 13C NMR of representative compounds; and HPLC traces of compounds 7, 16, and 23 (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_002.pdf">PDF</a>)Homology (docking) models of BRD4_5BT4_Cpd7 (UMB276) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_003.pdb">PDB</a>)Homology (docking) models of BRD4_5BT4_Cpd-16 (UMB295) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_004.pdb">PDB</a>)Homology (docking) models of BRD4_5BT4_Cpd-23 (UMB298) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_005.pdb">PDB</a>)Homology (docking) models of CBP_4NR7_Cpd-3 (UMB274) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_006.pdb">PDB</a>)Homology (docking) models of CBP_4NR7_Cpd-4 (UMB278) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_007.pdb">PDB</a>)Homology (docking) models of CBP_4NR7_Cpd-7 (UMB276) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_008.pdb">PDB</a>)Homology (docking) models of CBP_4NR7_Cpd-16 (UMB295) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_009.pdb">PDB</a>)Homology (docking) models of CBP_4NR7_Cpd-23 (UMB298) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_010.pdb">PDB</a>)Cocrystallographic data of compound 23 (UMB298) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c02232/suppl_file/jm0c02232_si_011.pdb">PDB</a>)This article has not yet been cited by other publications.

Reengineered BI‐DIME Ligand Core Based on Computer Modeling to Increase Selectivity in Asymmetric Suzuki–Miyaura Coupling for the Challenging Axially Chiral HIV Integrase Inhibitor

Concise and Practical Asymmetric Synthesis of a Challenging Atropisomeric HIV Integrase Inhibitor.

Molecular design and evaluation of aza-polycyclic carbamoyl pyridones as HIV-1 integrase strand transfer inhibitors

Screening Novel HIV-1 Protease Inhibitors Based on the Substrate Envelope Hypothesis

Bioisosterism-based Design and Enantiomeric Profiling of Chiral Hydroxyl-Substituted Biphenyl-Diarylpyrimidine Nonnucleoside HIV-1 Reverse Transcriptase Inhibitors.

Atom-based 3D-QSAR, molecular docking, DFT, and simulation studies of acylhydrazone, hydrazine, and diazene derivatives as IN-LEDGF/p75 inhibitors

Efficient Chiral Monophosphorus Ligands for Asymmetric Suzuki-Miyaura Coupling Reactions.

Design of Biphenyl-Substituted Diarylpyrimidines with a Cyanomethyl Linker as HIV-1 NNRTIs via a Molecular Hybridization Strategy.

Design, Synthesis, Biochemical, and Antiviral Evaluations of C6 Benzyl and C6 Biarylmethyl Substituted 2-Hydroxylisoquinoline-1,3-diones: Dual Inhibition against HIV Reverse Transcriptase-Associated RNase H and Polymerase with Antiviral Activities

Effective BI‐DIME Ligand for Suzuki–Miyaura Cross‐Coupling Reactions in Water with 500 Ppm Palladium Loading and Triton X

Structure-Based Design and Discovery of Pyridyl-Bearing Fused Bicyclic HIV-1 Inhibitors: Synthesis, Biological Characterization, and Molecular Modeling Studies

Structure-based design, synthesis, and biological characterization of indolylarylsulfone derivatives as novel human immunodeficiency virus type 1 inhibitors with potent antiviral activities and favorable drug-like profiles

Synthesis and Biological Evaluation of New Conformationally Restricted S-DABO Hybrids As Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase

Asymmetric Construction of 3,4-Diamino Pyrrolidines Via Chiral N,O-Ligand/Cu(I) Catalyzed 1,3-Dipolar Cycloaddition of Azomethine Ylides with Β-Phthalimidonitroethene.

Identification of new triazolo annulated dipyridodiazepine derivatives as HIV-1 reverse transcriptase inhibitors: Design, synthesis, DFT, molecular modelling and in silico studies

Conformational restriction design of thiophene-biphenyl-DAPY HIV-1 non-nucleoside reverse transcriptase inhibitors.

Development of Dimethylisoxazole-Attached Imidazo[1,2- a ]pyridines as Potent and Selective CBP/P300 Inhibitors

Structure based design and evaluation of benzoheterocycle derivatives as potential dual HIV-1 protease and reverse transcriptase inhibitors

Pharmacophore-fusing Design of Pyrimidine Sulfonylacetanilides As Potent Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase.

Improving the Positional Adaptability: Structure-Based Design of Biphenyl-Substituted Diaryltriazines As Novel Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors

Structure-guided Design of Novel Biphenyl-Quinazoline Derivatives As Potent Non-Nucleoside Reverse Transcriptase Inhibitors Featuring Improved Anti-Resistance, Selectivity, and Solubility